NEWS
Flowserve expands pump manufacturing in India
F
lowserve Corp is investing US$30 million to expand and upgrade its pump manufacturing facilities in Coimbatore, India. Flowserve will add a third facility to its Coimbatore campus that will produce highenergy pumps used in nuclear and fossil fuel power plants. The Flowserve Coimbatore campus already has two manufacturing facilities that produce a wide range of industrial and engineered pumps. The new facility should be completed in the fourth quarter of 2012. “The addition of this third manufacturing facility allows Flowserve to expand our Coimbatore product portfolio to include a broader range of engineered pumps,” explained Tom Ferguson, president, Flowserve Flow Solutions Group. “This key strategic initiative will give Flowserve a local source for high-energy pumps and allow us to participate in the rapid growth in both the nuclear and fossil fuel power generation markets in India,” added Ferguson.
our development in accordance with the strategy, presented during the IPO. With the intended acquisition, taking into account our marketing and R&D capabilities, HMS Group will be able to substantially increase revenues of the Plant, to broaden our company’s product portfolio, and to provide our clients with more integrated solutions in oil refining and petrochemicals.” The HMS Group has also acquired 98.59% of the share capital of oilfield equipment manufacturer Sibneftemash for RUB1.29 billion. Sibneftemash, located in the Tyumen region of the Russian Federation, designs, manufactures and supplies a range of equipment and appliances, including cementing pumps, for the drilling and production of oil and gas and well servicing. Commenting on the Sibneftemash acquisition, Molchanov said: “We look forward to new growth opportunities in the booming market of oilfield development. As a result of this deal HMS Group further improves its ability to offer comprehensive solutions to its clients. We believe that this acquisition improves the potential to significantly increase our revenues from the oilfield equipment market in the future.” For further information, visit www.grouphms.com and www.sibneftemash.ru
For further information, visit www.flowserve.com
Weir to sell HMS Group to acquire Cathcart site Belarussian centrifugal to ClydeUnion pump maker eir Group is selling its former
R
ussia’s HMS Group is acquiring 57% of the share capital of centrifugal pump manufacturer Bobruisk Machine Building Plant in a deal valued at US$9.6 million. Based in Bobruisk, Belarus, Bobruisk Machine Building Plant is one of the largest manufacturers of specialist centrifugal pumps in the CIS. With the acquisition of Bobruisk Machine Building Plant, HMS Group will enter the “hot cycle” oil refining pumps and related equipment market, and acquire new technologies. Bobruisk Machine Building Plant complements the existing business of HMS Group in “cold cycle” oil refining pumps. Artem Molchanov, managing director (CEO) of HMS Group, said: “We continue 16
Pump Industry Analyst
W
Weir Pumps site at Cathcart, Glasgow to ClydeUnion for £25 million. ClydeUnion has been leasing the site from Weir since the company acquired the Weir Pumps, Glasgow business in 2007. “The deal to sell our Cathcart site makes sense for both the Weir Group and ClydeUnion. We are pleased that the sale will support the future of the ClydeUnion business as they continue to provide employment at engineering and manufacturing operations in Glasgow,” said Keith Cochrane, chief executive of Weir. The sale of the site should be completed by the end of this year.
Editorial Office: Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom Tel: +44 (0)1865 843695 Fax: +44 (0)1865 843933 Web: www.pumpindustryanalyst.com Editor: Roisin Reidy E-mail:
[email protected] Production Support Manager: Lin Lucas E-mail:
[email protected] Publisher: Greg Valero E-mail:
[email protected] Subscription Information An annual subscription to Pump Industry Analyst includes 12 issues and online access for up to 5 users. Prices: 1176 for all European countries & Iran US$1319 for all countries except Europe and Japan ¥156 345 for Japan (Prices valid until 31 December 2011) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971/ Email:
[email protected], or via www.pumpindustryanalyst.com. Subscriptions run for 12 months, from the date payment is received. Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, email: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 207 436 5931; fax: (+44) 207 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) LImited 12979
For further information, visit www.weir.co.uk and www.clydeunion.com
August 2011